Viridian Therapeutics, Inc. $VRDN Shares Sold by Elmind Capital LP

Elmind Capital LP trimmed its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 37.7% in the first quarter, Holdings Channel reports. The firm owned 534,931 shares of the company’s stock after selling 323,700 shares during the period. Viridian Therapeutics makes up 3.0% of Elmind Capital LP’s portfolio, making the stock its 12th biggest position. Elmind Capital LP’s holdings in Viridian Therapeutics were worth $10,463,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Viridian Therapeutics by 1.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock valued at $669,000 after purchasing an additional 876 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Viridian Therapeutics by 33.8% in the first quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock worth $16,595,000 after buying an additional 310,998 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Viridian Therapeutics by 12.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 130,570 shares of the company’s stock valued at $1,760,000 after buying an additional 14,788 shares in the last quarter. Envestnet Asset Management Inc. acquired a new stake in shares of Viridian Therapeutics in the second quarter valued at about $187,000. Finally, Creative Planning purchased a new stake in shares of Viridian Therapeutics during the 2nd quarter valued at about $179,000.

Insider Buying and Selling at Viridian Therapeutics

In other news, Director Fairmount Funds Management Llc bought 1,176,470 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was bought at an average price of $17.00 per share, for a total transaction of $19,999,990.00. Following the transaction, the director owned 5,090,928 shares in the company, valued at $86,545,776. The trade was a 30.05% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 2.40% of the company’s stock.

Wall Street Analyst Weigh In

VRDN has been the topic of several recent research reports. Truist Financial boosted their price target on Viridian Therapeutics from $35.00 to $38.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Evercore set a $26.00 price objective on shares of Viridian Therapeutics in a research report on Friday, May 15th. Wedbush lifted their price objective on shares of Viridian Therapeutics from $32.00 to $43.00 and gave the company an “outperform” rating in a research note on Tuesday, June 30th. HC Wainwright reduced their target price on shares of Viridian Therapeutics from $34.00 to $22.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Finally, Weiss Ratings downgraded shares of Viridian Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. Thirteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Viridian Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $38.79.

Viridian Therapeutics Trading Up 2.2%

NASDAQ:VRDN opened at $19.70 on Tuesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 15.15 and a current ratio of 15.15. Viridian Therapeutics, Inc. has a one year low of $13.18 and a one year high of $34.29. The business’s 50-day simple moving average is $17.77 and its 200 day simple moving average is $22.33. The stock has a market cap of $2.03 billion, a price-to-earnings ratio of -5.93 and a beta of 0.90.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.90) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.16. Viridian Therapeutics had a negative net margin of 490.31% and a negative return on equity of 80.19%. The business had revenue of $0.14 million during the quarter, compared to analyst estimates of $0.04 million. During the same quarter in the previous year, the firm earned ($0.87) earnings per share. The business’s revenue was up 95.8% compared to the same quarter last year. As a group, sell-side analysts predict that Viridian Therapeutics, Inc. will post -3.87 earnings per share for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.